Suzuki K, Moriyama N, Yokose T, Nakaya Y, Ishihara T, Niho S, Nagai K, Esumi H
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba.
Jpn J Cancer Res. 1998 Jan;89(1):89-95. doi: 10.1111/j.1349-7006.1998.tb00484.x.
Although percutaneous ethanol injection is widely used to treat hepatic tumors, this technique has not been applied to lung tumors. We performed a preliminary experiment with percutaneous ethanol injection into the rabbit lung, and evaluated the local and systemic effects of absolute ethanol injection on pulmonary structures in order to assess the feasibility and safety of this technique as a local treatment for human lung tumors. Percutaneous injection of absolute ethanol into the rabbit lung was performed under CT guidance. The volume of ethanol injected ranged from 0.6 to 1.0 ml (approximately 0.2-0.5 ml/kg). Follow-up CT scans were performed 1, 2, 7 and 30 days after the injection. The animals were killed at intervals (range: 3 h-30 days), and the lung was examined histologically. The ethanol was well tolerated and did not induce significant systemic side-effects. All doses induced necrosis in the injected lung, but none was lethal. Although ethanol spilling into the thoracic cavity induced effusion and pleuritis, these reactions were manageable. Alcohol injection produced an area of necrosis surrounded by pulmonary edema associated with polymorphonuclear cells invasion within 24 h; moreover, granulation change, epithelial regeneration, and alveolar septal fibrosis had appeared by one week. The necrosis was sometimes multifocal, probably due to transbronchial spread of the injected ethanol. In conclusion, the feasibility and safety of absolute ethanol injection were confirmed. Neither severe systemic side effects nor lethal extensive necrosis were observed with injected ethanol; however, an unexpected side effect, multifocal necrosis, was seen. The latter reaction suggests that careful observation and care would be essential after alcohol injection into the lung.
尽管经皮乙醇注射广泛用于治疗肝脏肿瘤,但该技术尚未应用于肺部肿瘤。我们对兔肺进行了经皮乙醇注射的初步实验,并评估了无水乙醇注射对肺部结构的局部和全身影响,以评估该技术作为人类肺部肿瘤局部治疗方法的可行性和安全性。在CT引导下对兔肺进行无水乙醇经皮注射。注入的乙醇体积为0.6至1.0毫升(约0.2 - 0.5毫升/千克)。注射后1、2、7和30天进行随访CT扫描。在不同时间间隔(范围:3小时 - 30天)处死动物,并对肺进行组织学检查。乙醇耐受性良好,未引起明显的全身副作用。所有剂量均在注射的肺中引起坏死,但无一例致死。尽管乙醇溢入胸腔会引起积液和胸膜炎,但这些反应是可控的。酒精注射在24小时内产生了一个由肺水肿包围的坏死区域,伴有多形核细胞浸润;此外,到一周时已出现肉芽组织变化、上皮再生和肺泡间隔纤维化。坏死有时是多灶性的,可能是由于注入的乙醇经支气管扩散所致。总之,证实了无水乙醇注射的可行性和安全性。注射乙醇未观察到严重的全身副作用或致命的广泛坏死;然而,出现了一个意外的副作用,即多灶性坏死。后一种反应表明,肺内注射酒精后仔细观察和护理至关重要。